Title:
PHARMACEUTICAL COMPOSITION, FOR ENHANCING MELANOMA TREATING EFFECT, COMPRISING OLIGODENDROCYTE TRANSCRIPTION FACTOR 2 INHIBITOR AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2022/131667
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for enhancing melanoma metastasis treating effect. More particularly, it has been confirmed that the melanoma preventing or treating effect of dabrafenib was notably enhanced when the composition comprising the oligodendrocyte transcription factor 2 (OLIG2) inhibitor was concomitantly administered with dabrafenib. The pharmaceutical composition of the present invention enables effective treatment of melanoma even when less dabrafenib is used than an existing dose, and thus can be free from the problem of toxicity and side effects.
Inventors:
HWANG JAE SUNG (KR)
LEE JI EUN (KR)
LEE JI EUN (KR)
Application Number:
PCT/KR2021/018584
Publication Date:
June 23, 2022
Filing Date:
December 09, 2021
Export Citation:
Assignee:
UNIV INDUSTRY COOPERATION GROUP KYUNG HEE UNIV (KR)
International Classes:
A61K48/00; A61K31/506; A61K31/7088; A61P35/00
Domestic Patent References:
| WO2019246262A2 | 2019-12-26 |
Foreign References:
| KR20180081591A | 2018-07-16 | |||
| JP2015521603A | 2015-07-30 | |||
| KR20150123328A | 2015-11-03 |
Other References:
LEE JI EUN, AHN SUNGJIN, JEONG HAENGDUENG, AN SEUNGCHAN, MYUNG CHEOL HWAN, LEE JEONG AH, HONG SUNG CHAN, KIM YOUN JIN, KIM JIN YOU: "Olig2 regulates p53-mediated apoptosis, migration and invasion of melanoma cells", SCIENTIFIC REPORTS, vol. 11, no. 1, 1 December 2021 (2021-12-01), pages 1 - 15, XP055942762, DOI: 10.1038/s41598-021-87438-x
Attorney, Agent or Firm:
ISIS IP LAW LLC (KR)
Download PDF: